Publications by authors named "G Radvanyi"
Article Synopsis
- TP53 mutations are linked to chemoresistance in chronic lymphocytic leukaemia (CLL) and can indicate the ineffectiveness of standard chemoimmunotherapy, prompting a need for better mutation assessment.* -
- In a study of 901 CLL patients, 17.5% had TP53 mutations, with nearly half being low-burden mutations, which raises questions about their clinical significance.* -
- Low-burden TP53 mutations led to earlier treatment initiation compared to patients without mutations, suggesting the need to reconsider the detection threshold for these mutations in diagnostics.*
In Hungary, the cost of lenalidomide-based therapy is covered only for relapsed multiple myeloma (MM) patients, therefore lenalidomide is typically used in the second-line either as part of a triplet with proteasome inhibitors or as a doublet. Lenalidomide-dexamethasone is a standard treatment approach for relapsed/refractory MM, and according to recent large randomized clinical trials (RCT, the standard arm of POLLUX, ASPIRE, TOURMALINE), the progression-free survival (PFS) is expected to be approximately 18 months. We surveyed ten Hungarian centers treating MM and collected data of 278 patients treated predominantly after 2016.
View Article and Find Full Text PDFBackground: Philadelphia negative myeloproliferative neoplasms (MPNs) are characterized by frequent mutations of driver genes including JAK2, CALR and MPL. While the influence of JAK2 V617F mutant allele burden on the clinical phenotype of MPN patients is well-described, the impact of CALR mutant allele burden on clinical features needs further investigation.
Patients And Methods: Quantitative assessment of JAK2 and CALR mutations was performed on diagnostic DNA samples from 425 essential thrombocythemia (ET) and 227 primary myelofibrosis patients using real-time quantitative PCR and fragment length analysis.
Follicular lymphoma is a lymphoid malignancy commonly showing slow progression which makes the treatment of the disease challenging. Rituximab monotherapy and rituximab added to standard chemotherapy has been proven to increase survival among patients with advanced stage of the disease. However, the benefit of a rituximab maintenance therapy after induction was still unclear at the time of the initiation of this study.
View Article and Find Full Text PDFArticle Synopsis
- TTP is linked to a deficiency of the ADAMTS-13 protease, leading to significant endothelial activation, but reliable clinical markers for this activation are lacking.
- In a study involving 54 TTP patients and 57 healthy controls, increased levels of CT-proET-1 and VWF were found in both acute and remission phases, though CT-proET-1 decreased by 22% in remission.
- The research indicates that endothelial activation in TTP correlates with alternative complement pathway activation, suggesting both factors play a role in TTP episodes in susceptible individuals.